companydata.dkcompanydata.dk
Back to company

AdaptVac ApS: Financial statements 2018

CVR: 38732730

AdaptVac ApS (CVR 38732730) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 431,961 and a net result of DKK 333,539. Equity amounted to DKK 63,518. The solvency ratio was 69.1%.

Gross Profit
431,961 kr.
Profit/Loss
333,539 kr.
Equity
63,518 kr.
Total Assets
91,866 kr.
Employees
0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on AdaptVac ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2018

AdaptVac ApS publishes interim reportJun 4, 2018

AdaptVac ApS has published its interim report for the period June 22, 2017 – December 31, 2017.

About AdaptVac ApS

AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.

Other financial years

2025202420232022202120202019